Equity grant gives Organogenesis (ORGO) director 48,828 RSUs vesting 2027
Organogenesis Holdings Inc. director Michael Joseph Driscoll received an equity grant of 48,828 restricted stock units (RSUs) of Class A common stock. This compensation-related acquisition, granted at no cash cost, will vest in full on February 15, 2027. Following the grant, Driscoll's direct Class A share balance stands at 215,707 shares.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP has launched an investigation into Organogenesis Holdings Inc. (NASDAQ: ORGO) following a significant stock price drop. The investigation concerns potential securities fraud after the Centers for Medicare & Medicaid Services withdrew Local Coverage Determinations related to skin substitute products, which analysts believe will increase competition for Organogenesis and led to a 10.14% decline in its stock. Investors affected by these events are encouraged to contact Pomerantz LLP for more information about joining a potential class action.
Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Invest In Growth?
Organogenesis Holdings (NASDAQ:ORGO) is analyzed for its growth prospects, focusing on its cash burn rate and cash runway. The company has a cash runway of approximately 15 months based on its September 2025 balance sheet and burned US$52m in the past year. Despite minimal revenue growth of 2.1%, its cash burn of US$52m represents a low 9.7% of its US$534m market capitalization, suggesting it could likely raise additional funds if needed without significant dilution.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP is investigating potential claims of securities fraud or other unlawful business practices against Organogenesis Holdings Inc. (NASDAQ: ORGO) and its officers. This investigation follows a 10.14% drop in Organogenesis's stock price after the Centers for Medicare & Medicaid Services withdrew final Local Coverage Determinations related to skin substitute grafts, which analysts believe will increase competition for the company. Investors are encouraged to contact Pomerantz LLP for more information regarding potential class action involvement.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc.
Pomerantz LLP is investigating Organogenesis Holdings Inc. (ORGO) on behalf of investors following a significant stock price drop. The investigation stems from the Centers for Medicare & Medicaid Services' withdrawal of Local Coverage Determinations related to skin substitute products, which analysts believe will increase competition for Organogenesis and led to a 10.14% stock decline on December 30, 2025. The firm is examining potential securities fraud or unlawful business practices by the company's officers and directors.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. (NASDAQ: ORGO) following a significant stock price drop. The investigation commenced after the Centers for Medicare & Medicaid Services withdrew Local Coverage Determinations related to skin substitute products, which analysts believe will increase competition for Organogenesis. This development led to a 10.14% fall in Organogenesis's stock price on December 30, 2025.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc.
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. (NASDAQ: ORGO) following a significant 10.14% stock price drop on December 30, 2025. This decline occurred after the Centers for Medicare & Medicaid Services withdrew Local Coverage Determinations, leading analysts to predict increased competition for Organogenesis. Investors who suffered losses are advised to contact Pomerantz LLP for more information regarding a potential class action lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP is investigating Organogenesis Holdings Inc. (NASDAQ: ORGO) following a significant stock price drop. The investigation concerns potential securities fraud after the Centers for Medicare & Medicaid Services withdrew Local Coverage Determinations related to skin substitute products, increasing competition for Organogenesis and leading to a 10.14% decline in its stock. Investors are encouraged to contact Pomerantz LLP for information regarding potential class action involvement.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. (NASDAQ: ORGO) on behalf of investors. The investigation follows a 10.14% drop in Organogenesis's stock price after the Centers for Medicare & Medicaid Services withdrew Local Coverage Determinations, which analysts predict will increase competition for the company. Investors are encouraged to contact Pomerantz LLP for more information regarding the class action investigation.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc.
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. (NASDAQ: ORGO) on behalf of investors. This investigation follows the Centers for Medicare & Medicaid Services' withdrawal of Local Coverage Determinations (LCDs) related to skin substitute grafts, which analysts believe will increase competition for Organogenesis. The company's stock subsequently fell by 10.14% on December 30, 2025, after this news.
Organogenesis Holdings extends leases for Canton facilities through 2032 By Investing.com
Organogenesis Holdings Inc. announced the extension of lease agreements for two facilities in Canton, Massachusetts, through December 31, 2032, with an option for renewal until 2034. These facilities are crucial for the company's manufacturing, operations, and research and development activities. The lease amendments were approved by the Audit Committee, considering that some major stockholders indirectly own the properties.
Organogenesis Holdings extends leases for Canton facilities through 2032
Organogenesis Holdings Inc. has extended the leases for its Canton, Massachusetts headquarters facilities through 2032, with an option for an additional two-year renewal. The lease amendments involved properties owned by significant shareholders and board members, and were approved by the Audit Committee. This news follows other recent developments such as a rolling Biologics License Application submission for its ReNu product and maintained analyst ratings.
Organogenesis Holdings extends leases for Canton facilities through 2032 By Investing.com
Organogenesis Holdings Inc. announced extensions for the leases of two facilities at its Canton, Massachusetts headquarters through December 31, 2032, with an option for an additional two-year renewal. These facilities are critical for manufacturing, operations, and R&D. The lease amendments, approved by the Audit Committee, involve properties partly owned by significant shareholders of Organogenesis.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. following a significant stock price drop. The investigation began after the Centers for Medicare & Medicaid Services withdrew Local Coverage Determinations related to skin substitute products, which analysts believe will increase competition for Organogenesis. This news led to a 10.14% decline in Organogenesis's stock price on December 30, 2025.
Organogenesis drops as Medicare to pull skin substitute LCDs (update)
Organogenesis (ORGO) and MiMedx (MDXG) shares dropped after the Centers for Medicare & Medicaid Services (CMS) withdrew Local Coverage Determinations (LCDs) related to certain skin substitute products that were set to take effect next year. The withdrawal is expected to increase market competition by allowing over 300 additional products, negatively impacting analyst confidence in Organogenesis's 2026 outlook.
Organogenesis director Nussdorf sells $1.59 million in shares By Investing.com
Organogenesis Holdings Inc. director Glenn H. Nussdorf sold 306,300 shares of Class A Common Stock for $1.59 million across three transactions between November 24 and November 26, 2025. Despite the sales occurring at prices slightly below the current trading price, analysts predict profitability for ORGO this year, with an expected EPS of $0.24 for FY2025. The company recently reported strong Q3 2025 revenue of $150.5 million, exceeding forecasts, and BTIG raised its price target for ORGO to $9.00 due to favorable reimbursement changes in the wound care market.
Organogenesis director Nussdorf sells $1.59 million in shares
Organogenesis Holdings Inc. director Glenn H. Nussdorf sold 306,300 shares of Class A Common Stock for $1.59 million across three transactions between November 24 and November 26, 2025. Despite the sales occurring below the current trading price, analysts expect Organogenesis to be profitable in 2025 with a forecasted EPS of $0.24. The company recently reported strong Q3 2025 revenues of $150.5 million, surpassing analyst forecasts.
Organogenesis Holdings Insider Sold Shares Worth $1,592,120, According to a Recent SEC Filing
An insider at Organogenesis Holdings Inc. (NASDAQ: ORGO) sold shares valued at $1,592,120, as reported in a recent SEC filing. The article highlights this transaction and lists other recent news and financial activities related to the company, including its Q3 2025 earnings and FDA application plans.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organogenesis Holdings Inc. (ORGO) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Organogenesis Holdings Inc. (ORGO) on behalf of investors. This follows a significant drop in Organogenesis's share price after its second Phase 3 ReNu trial failed to meet its primary endpoint for pain reduction. The firm is encouraging shareholders to come forward and assist in the investigation.
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Organogenesis Holdings Inc. announced inducement grants to Michael Catarina, its new Chief Technology Officer. The grants include non-statutory stock options for 82,542 shares and restricted stock units for 47,962 shares of Class A common stock. These awards were made as an inducement for his employment, adhering to Nasdaq Listing Rule 5635(c)(4).
Organogenesis Holdings Inc. Commends CMS on Payment Reform for Skin Substitutes and CTPs Under CY 2026 Fee Schedule | ORGO Stock News
Organogenesis Holdings Inc. has praised the Centers for Medicare & Medicaid Services (CMS) for its payment reform concerning skin substitutes and cellular tissue-based products under the CY 2026 Physician Fee Schedule. CEO Gary S. Gillheeney stated that this new policy, which includes per centimeter square payment and FDA classifications, is expected to enhance access to PMA products and curb existing abuses. The company believes this positions them strongly in the regenerative medicine market for 2026 and beyond.
Organogenesis Holdings Inc. (ORGO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Organogenesis Holdings Inc. (ORGO) after the company announced on September 25, 2025, that its second Phase 3 trial for ReNu failed to meet its primary endpoint, leading to a nearly 12.4% drop in stock price. The law firm is encouraging shareholders who purchased Organogenesis securities to contact them regarding potential claims. They represent investors on a contingency fee basis for securities fraud class actions and shareholder derivative suits.
Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO
DJS Law Group is investigating Organogenesis Holdings Inc. for potential securities fraud violations. This investigation follows a 12.39% drop in Organogenesis shares on September 26, 2025, after the company announced its ReNu phase 3 trial failed to meet its primary endpoint of pain reduction. Investors who suffered losses are encouraged to contact DJS Law Group to discuss their rights.
Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO
Organogenesis Holdings Inc. is under investigation for potential securities fraud violations after admitting that its ReNu phase 3 trial failed to meet its primary endpoint, causing a 12.39% stock drop. The DJS Law Group is initiating the investigation to determine if the company issued misleading statements or withheld pertinent information from investors. Shareholders who experienced a loss are encouraged to contact the firm.
Organogenesis Holdings Inc. Securities Lawsuit Investigation - Claim Depot
Claim Depot is investigating Organogenesis Holdings Inc. for potential securities law violations due to alleged misleading statements regarding its ReNu clinical program between May 2024 and September 2025. Investors who purchased securities during this period and suffered losses may be eligible for compensation. The investigation could lead to a class action lawsuit, and affected investors are urged to act promptly.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. (ORGO) on behalf of investors. This investigation follows a disclosure by Organogenesis that its cryopreserved amniotic suspension allograft ReNu failed to meet its primary endpoint in a second phase 3 trial, leading to a significant drop in its stock price. Pomerantz LLP encourages affected investors to contact their firm for more information regarding a potential class action.
Organogenesis Holdings Inc. Announced Results from Second Phase 3 Trial of ReNu for Knee Osteoarthritis Pain Management
Organogenesis Holdings Inc. announced that its second Phase 3 trial for ReNu, a therapy for knee osteoarthritis, did not meet its primary endpoint of statistical significance but showed numerical pain reduction. Despite this, the company will pursue a Biologics License Application with the FDA, combining data from both Phase 3 trials and highlighting ReNu's favorable safety profile and RMAT designation. Insiders have recently purchased ORGO stock, and institutional investors show mixed activity.
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025
Organogenesis Holdings Inc. announced that it will report its first-quarter fiscal year 2025 financial results after the market closes on Thursday, May 8, 2025. The company will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the results and provide a corporate update, including a question and answer session. Investors can access the live webcast via the company's website.
ORGO Stock Price, News & Analysis
Organogenesis Holdings Inc. (NASDAQ: ORGO) is a regenerative medicine company focusing on advanced wound care and surgical & sports medicine markets. The article details its business operations, product portfolio including ReNu for knee osteoarthritis, financial performance, regulatory efforts, and corporate governance. Key highlights include the company's BLA submission plan for ReNu and its role in the skin substitutes/CTP market.
Organogenesis signs Smithfield lease with subsidies in hand
Organogenesis has signed a lease for a biotech facility in Smithfield, Rhode Island, securing subsidies for the expansion. The regenerative medicine company specializes in advanced wound care products. This move follows previous related activities in the Rhode Island life sciences sector.
Deadline Tomorrow Reminder: The Schall Law Firm Encourages Investors in Organogenesis Holdings Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm is reminding investors who suffered losses of $100,000 or more in Organogenesis Holdings Inc. to contact the firm regarding a class action lawsuit. The lawsuit alleges that Organogenesis made false and misleading statements by improperly billing the government for its products and influencing physicians through reimbursement programs. Investors who purchased securities between March 17, 2021, and October 11, 2021, are encouraged to participate before February 8, 2022.
TUESDAY DEADLINE: Organogenesis Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – ORGO
Robbins Geller Rudman & Dowd LLP reminds investors of Organogenesis Holdings Inc. (NASDAQ: ORGO) that they have until February 8, 2022, to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that Organogenesis misleadingly billed the federal government for its products and improperly induced doctors to use them, causing an unsustainable revenue stream. Investors who purchased ORGO securities between March 17, 2021, and October 11, 2021, and suffered significant losses, are encouraged to come forward.
TUESDAY DEADLINE: Organogenesis Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – ORGO
Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against Organogenesis Holdings Inc. (NASDAQ: ORGO) for investors who purchased securities between March 17, 2021, and October 11, 2021. Investors have until February 8, 2022, to seek appointment as lead plaintiff. The lawsuit alleges Organogenesis improperly billed the federal government for its Affinity and PuraPly XT products and used lucrative reimbursements to induce doctors, leading to unsustainable revenue and profits.
Workboat Indexes | WorkBoat - TUESDAY DEADLINE: Organogenesis Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – ORGO
Robbins Geller Rudman & Dowd LLP reminds investors of Organogenesis Holdings Inc. (ORGO) that they have until February 8, 2022, to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that Organogenesis made false and misleading statements regarding its billing practices for Affinity and PuraPly XT products, improperly inducing doctors and overcharging the federal government. This led to an unsustainable revenue model and a significant stock price drop following an anonymous short report.
Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Organogenesis Holdings Inc. (ORGO) Investors of Filing Deadline in Class Action Lawsuit
Kessler Topaz Meltzer & Check, LLP is reminding Organogenesis Holdings Inc. (ORGO) investors that a securities class action lawsuit has been filed against the company, alleging federal securities law violations due to misleading statements. Investors who suffered losses between March 17, 2021, and October 11, 2021, have until February 8, 2022, to seek lead plaintiff status. The lawsuit stems from allegations that Organogenesis improperly billed the federal government and used large rebates to incentivize doctors, causing its stock price to fall.
Deadline Tuesday Notice: The Schall Law Firm Encourages Investors in Organogenesis Holdings Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm is encouraging investors in Organogenesis Holdings Inc. (NASDAQ: ORGO) who suffered losses of $100,000 or more to contact the firm regarding a class action lawsuit. The lawsuit alleges that Organogenesis made false and misleading statements to the market by improperly billing the government for its products and influencing physicians through reimbursement programs. Investors who purchased securities between March 17, 2021, and October 11, 2021, are urged to participate before February 8, 2022.
Salt Lake City News, Weather, Sports, Breaking News | KUTV - The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Organogenesis Holdings Inc. (ORGO)
The Law Offices of Frank R. Cruz reminds investors of the February 8, 2022 deadline to file as lead plaintiff in a class action lawsuit against Organogenesis Holdings Inc. (ORGO). The lawsuit alleges that Organogenesis improperly billed the federal government for its Affinity and PuraPly XT products by setting inflated prices and inducing doctors with lucrative reimbursements, leading to unsustainable revenue and profits. Organogenesis's stock dropped 14% after a report surfaced detailing these alleged practices.
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Organogenesis Holdings Inc. (ORGO)
The Law Offices of Frank R. Cruz is reminding investors of the upcoming February 8, 2022 deadline to file as lead plaintiff in a class action lawsuit against Organogenesis Holdings Inc. (ORGO). The lawsuit alleges that Organogenesis improperly billed the federal government for its Affinity and PuraPly XT products by setting inflated prices and inducing doctors with lucrative reimbursements, leading to unsustainable revenue and profits. Organogenesis's stock fell 14% after an anonymous report exposed these alleged practices in October 2021.
Tuesday Deadline Reminder: The Schall Law Firm Encourages Investors in Organogenesis Holdings Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm is reminding investors of Organogenesis Holdings Inc. (NASDAQ: ORGO) about a class action lawsuit for alleged securities violations between March 17, 2021, and October 11, 2021. The firm encourages investors who suffered losses of $100,000 to contact them before the February 8, 2022 deadline. The lawsuit claims Organogenesis made false and misleading statements regarding improper billing practices and influencing physicians.
Salt Lake City News, Weather, Sports, Breaking News | KUTV - Investor Action Reminder: The Schall Law Firm Encourages Investors in Organogenesis Holdings Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm is encouraging investors who suffered losses of $100,000 or more in Organogenesis Holdings Inc. (NASDAQ: ORGO) to join a class action lawsuit. The lawsuit alleges that Organogenesis made false and misleading statements regarding its billing practices for Affinity and PuraPly XT, leading to investor damages during the Class Period between March 17, 2021, and October 11, 2021. Investors have until February 8, 2022, to contact the firm.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Organogenesis Holdings Inc. of Class Action Lawsuit and Upcoming Deadline - ORGO
Pomerantz LLP has filed a class action lawsuit against Organogenesis Holdings Inc. (NASDAQ: ORGO) on behalf of shareholders who purchased securities between March 17, 2021, and October 11, 2021. The lawsuit alleges that Organogenesis misleadingly billed the federal government for its Affinity and PuraPly XT products at inflated prices and improperly induced doctors to use them. Shareholders have until February 8, 2022, to apply to be lead plaintiff.
ROSEN, A LEADING LAW FIRM, Encourages Organogenesis Holdings Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action ORGO
Rosen Law Firm is encouraging investors of Organogenesis Holdings Inc. (NASDAQ: ORGO) who incurred losses exceeding $100K to secure legal counsel before the February 8, 2022, lead plaintiff deadline in a securities class action. The lawsuit alleges that Organogenesis improperly billed the federal government for its Affinity and PuraPly XT products by setting inflated prices and inducing doctors to use them through lucrative reimbursements, leading to unsustainable revenue and profits. Investors who purchased Organogenesis securities between March 17, 2021, and October 11, 2021, may be entitled to compensation.
Shareholder Action Alert: The Schall Law Firm Encourages Investors in Organogenesis Holdings Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm has announced a class action lawsuit against Organogenesis Holdings Inc. for alleged violations of securities laws. Investors who purchased Organogenesis securities between March 17, 2021, and October 11, 2021, and suffered losses of $100,000 or more are encouraged to contact the firm. The lawsuit claims Organogenesis made false and misleading statements regarding improper billing practices and influencing physicians through reimbursement programs.
Investor Action Alert: The Schall Law Firm Encourages Investors in Organogenesis Holdings Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm has announced a class action lawsuit against Organogenesis Holdings Inc. (NASDAQ: ORGO) for alleged violations of securities laws. The firm is encouraging investors who suffered losses of $100,000 or more and purchased the company's securities between March 17, 2021, and October 11, 2021, to contact them before February 8, 2022. The lawsuit claims Organogenesis made false and misleading statements about its billing practices, specifically regarding Affinity and PuraPly XT products, by setting high prices and influencing physicians through reimbursement programs.
Shareholder Action Reminder: The Schall Law Firm Encourages Investors in Organogenesis Holdings Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm is reminding investors of Organogenesis Holdings Inc. (NASDAQ: ORGO) about a class action lawsuit. This lawsuit targets Organogenesis for alleged violations of securities laws, specifically regarding supposedly false and misleading statements about the company's billing practices for government-funded products. Investors who purchased ORGO securities between March 17, 2021, and October 11, 2021, and suffered losses are encouraged to contact the firm by February 8, 2022, to discuss their rights.
ORGO Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Organogenesis Holdings, Inc. (ORGO)
Robbins LLP has announced a class action lawsuit against Organogenesis Holdings, Inc. (ORGO) on behalf of investors who purchased securities between March 17, 2021, and October 11, 2021. The lawsuit alleges that Organogenesis improperly billed the federal government for its Affinity and PuraPly XT products by setting inflated prices and inducing doctors with lucrative reimbursements. This misconduct led to unsustainable revenues and a subsequent drop in stock price following an anonymous report revealing the alleged practices.
Robbins LLP Reminds Investors of Class Action Against Organogenesis Holdings, Inc. (ORGO)
Robbins LLP has announced a class action lawsuit against Organogenesis Holdings, Inc. (ORGO) on behalf of investors who purchased securities between March 17, 2021, and October 11, 2021. The complaint alleges that Organogenesis improperly billed the federal government for its Affinity and PuraPly XT products by setting excessively high prices and inducing doctors to use them through lucrative reimbursements, making a substantial portion of its revenue unsustainable. The truth emerged on October 12, 2021, causing the stock price to drop over 14%.
ORGO Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Organogenesis Holdings Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC has notified investors of a class action lawsuit filed against Organogenesis Holdings Inc. (NASDAQ: ORGO) and its officers. The lawsuit alleges that Organogenesis made materially false and misleading statements regarding its business operations, specifically concerning improper billing practices and inducement strategies for its Affinity and PuraPly XT products, which led to unsustainable revenue and profits. Shareholders who purchased Organogenesis securities between March 17, 2021, and October 11, 2021, are encouraged to join the case and have until February 8, 2022, to request to be appointed as lead plaintiff.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Organogenesis Holdings Inc. Investors to Secure Counsel Before Important February 8 Deadline in Securities Class Action – ORGO
Rosen Law Firm is encouraging investors of Organogenesis Holdings Inc. (NASDAQ: ORGO) to join a securities class action lawsuit by the February 8, 2022, lead plaintiff deadline. The lawsuit alleges that Organogenesis made false and misleading statements regarding its billing practices for Affinity and PuraPly XT products, claiming the company set prices artificially high and improperly induced doctors to use them, leading to unsustainable revenue and profits. Investors who purchased Organogenesis securities between March 17, 2021, and October 11, 2021, may be entitled to compensation.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Organogenesis Holdings Inc. Investors to Secure Counsel Before Important February 8 Deadline in Securities Class Action – ORGO
Rosen Law Firm is encouraging investors of Organogenesis Holdings Inc. (NASDAQ: ORGO) who purchased securities between March 17, 2021, and October 11, 2021, to secure legal counsel before the February 8, 2022, lead plaintiff deadline for a securities class action. The lawsuit alleges that Organogenesis improperly billed the federal government for its Affinity and PuraPly XT products by setting inflated prices and inducing doctors to use them through lucrative reimbursements, leading to unsustainable revenue and profits. Investors who suffered damages due to these alleged false and misleading statements may be entitled to compensation.
